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1. Introduction
Migraine and other severe headache disorders, which affect an estimated 16–23% of the 
U.S. population [40], are a major cause of personal suffering and functional impairment [29; 
40]. Patients with chronic headaches often have high levels of psychological distress [8], 
including depressive symptoms [23; 37], anxiety [25; 41; 54], and somatization [21; 48]. 
Psychological distress can exacerbate the adverse impact of headache on health-related 
quality of life (HRQOL) [22], and may reduce efficacy of headache interventions [22]. 
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Interventions targeting both physical and psychological dimensions of pain may produce 
maximal improvements in HRQOL.
1.1. Can targeted dietary changes modulate physical and psychological pain?
Dietary n-3 and n-6 fatty acids could alter biochemical mechanisms underlying physical and 
psychological dimensions of pain. Notably, n-3 and n-6 fatty acids are major structural 
components of neuronal, glial, and immune cell membranes [38], and biosynthetic 
precursors to several families of bioactive lipid mediators (e.g., eicosanoids, endovanilloids, 
resolvins)[34]. With several notable exceptions [19; 46], lipid mediators derived from n-6 
fatty acids have pronociceptive properties [2; 32; 51], while mediators derived from n-3 fatty 
acids have antinociceptive actions [27; 31; 39; 53]. n-3 and n-6 fatty acids are also proposed 
to modulate the risk of developing depression and anxiety [1; 4; 16; 18; 24; 44; 50]. 
Therefore, in addition to physical pain relief, targeted manipulation of dietary n-3 and n-6 
fatty acids may be able to reduce psychological distress and enhance HRQOL.
1.2. The Chronic Daily Headache (CDH) trial
The CDH trial was a randomized, parallel-group, 12-week trial designed to test the 
biochemical and clinical effects of a diet high in n-3 and low in n-6 fatty acids (the H3-L6 
intervention) compared to a diet low in n-6 fatty acids (the L6 intervention) in a population 
with chronic headaches. In a previous manuscript [34], we reported that the H3-L6 
intervention produced statistically significant, clinically relevant improvements in headache 
frequency and severity (Figure 1) [26; 34; 36]. However, we do not yet know whether this 
pain relief was accompanied by beneficial effects on psychological dimensions of pain or 
HRQOL. Nor do we know how the changes in individual n-3 and n-6 fatty acids in 
circulation relate to headache pain, psychological distress, and HRQOL.
The objectives of this paper are: (1) to determine the effect of the interventions on 
psychological distress and HRQOL, as measured by the Brief Symptom Inventory (BSI-18) 
and the Medical Outcomes Study Short Forms 12 (SF-12), respectively; (2) to examine the 
effect of the dietary interventions on the number of cases with substantial physical or mental 
impairments as defined by cutoff values in BSI-18, SF-12, Headache Impact Test-6 (HIT-6), 
and the number of Headache Days per month; and (3) examine how changes in n-3 and n-6 
fatty acids relate to headache pain, psychological distress, and HRQOL.
2. Material and Methods
2.1 Trial overview
The trial protocol, detailed dietary composition and intervention methods, and the primary 
pain-related and biochemical outcomes were previously described [26; 34; 35; 47]. Briefly, 
adult women and men with any primary headache type meeting our CDH criteria—
headaches ≥4 hours per day and ≥15 days per month for at least 3 months as well as a 
headache history of ≥2 years with headaches managed by a physician—were recruited to 
participate in an outpatient dietary trial. Inclusion and exclusion criteria are shown in 
Supplementary Table S1. After the nature and possible consequences of the trial were 
explained, all participants provided written informed consent. During the 4-week pre-
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intervention run-in phase, participants continued their usual care and habitual diets and 
recorded headache characteristics and medication use in an online daily headache diary. 
Upon completion of the run-in phase, participants were randomized to either the H3-L6 or 
L6 intervention, to be maintained for 12 weeks. Participants were advised to continue seeing 
their regular headache physician for usual care throughout the trial. The trial was conducted 
at the University of North Carolina at Chapel Hill (UNC) from April 2009 to November 
2011. Trial procedures were approved by the UNC Institutional Review Board. This trial is 
registered under ClinicalTrials.gov (NCT01157208).
2.2. Randomization and masking
Randomization and masking procedures were previously described [34]. Briefly, participants 
were randomized by the dietitian using an on-line, uneditable treatment assignment 
algorithm with a random permuted block design using a number sequence (1:1 allocation 
ratio). Only the dietitian was unmasked by necessity at randomization in order to assign 
patients to their group and to administer the interventions. Participants were provided dietary 
advice and foods in accordance with their assigned intervention, and were masked to the 
nature and content of the other group’s intervention. All other investigators, staff, and each 
participant’s personal physician were masked to group assignment for the full duration of 
the trial.
2.3. Dietary interventions
The H3-L6 intervention was designed to reduce dietary n-6 linoleic acid (LA), and 
concurrently increase dietary n-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA). The L6 intervention was designed to reduce dietary n-6 LA, and to maintain the low 
n-3 EPA and DHA intakes typical of U.S. diets [26]. The nutrient intakes of the two groups 
were previously published [26] and are summarized in Supplementary Table S3. Foods 
meeting nutrient targets were provided to participants sufficient for two meals and two 
snacks per day. The interventions were designed to be equally credible and equivalent with 
respect to: (1) macronutrient and caloric intake, (2) the amounts of study foods provided, (3) 
interactions with the study dietitian and other investigators, and (4) the intensity and breadth 
of the dietary advice and intervention materials [26]. A registered dietitian administered 
dietary counseling at randomization and at regular 2-week intervals throughout the 12-week 
intervention phase.
2.4. Measures of psychological distress and HRQOL
Psychological distress was assessed at baseline and week 12 with the BSI-18, which is a 
self-reported survey for screening psychological distress and measuring treatment outcomes 
[7]. The BSI-18 assesses three symptom dimensions—somatization, depression, and anxiety
—which together form the global severity index (GSI) of psychological distress. A higher 
BSI-18 score indicates a greater degree of psychological distress. For this study, we removed 
the suicide query from the depression dimension and replaced its value with the mean of the 
remaining depression questions.
HRQOL was assessed at baseline and week 12 with the SF-12 [16] which is a self-reported 
survey for measuring physical and mental health and function. The SF-12 [19] contains eight 
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subdomains—physical functioning, role physical, bodily pain, general health, vitality, role 
emotional, mental health, and social functioning—which in turn comprise separate physical 
and mental health summary measures. Lower SF-12 scores indicate a lower quality of 
physical and mental health. The SF-12 was found to be reliable, valid, and responsive to 
change in a population of chronic-back-pain patients, and has been employed in migraine 
research [19].
In addition to those surveys, both psychological distress and HRQOL were assessed at 
baseline and week 12 with the HIT-6, which is a self-reported survey for measuring 
headache-related disability [3; 45]. The HIT-6 encompasses the health dimensions of pain, 
social functioning, role functioning, vitality, cognitive functioning, and psychological 
distress. Higher HIT-6 scores indicate a higher level of headache-related disability.
2.5 Cutoff values for cases of substantial physical or mental impairment
Cases of substantial impairment were defined as those subjects with BSI-18 scores > 60, 
SF-12 physical and mental health summary scores < 40, HIT-6 scores ≥ 56, or ≥ 20 
headache days per month. Since the BSI-18 and SF-12 scores are standardized (norm-
referenced) with 50 points equal to the mean of the general population, we use a one 
standard deviation (10 points) difference to determine the cutoff points. This means, for 
example, that people with a BSI-18 score of 60 or above function at a level lower than 84% 
of the general population. Also, an SF-12 score of < 40 can be interpreted as moderate to 
severe disability [42]. For HIT-6, subjects with scores ≥ 56 range from having “substantial 
impact on life” corresponding to severe pain to having “very severe impact” corresponding 
to disabling pain [3]. We also classified subjects with 20 or more headache days per month 
as having substantial pain-related impairment.
2.6. Medication use
Daily headache-related medication use was captured in the online headache diary. 
Medications were classified into 3 broad categories: acute, preventive, or adjunctive 
(Supplementary Table S2). Medication change was previously reported as an exploratory 
outcome measure [34]. Participants in the H3-L6 group significantly reduced their use of 
acute medications and adjunctive medications compared to baseline. Participants did not 
significantly alter their use of preventive medications in either group.
2.7. Sample collection and laboratory analysis of n-3 and n-6 fatty acids
Sample preparation and analyses were performed by investigators who were blinded to study 
protocol and clinical data. Fasting blood was drawn at baseline and after 12-weeks of diet 
exposure. Plasma fatty acids were analyzed at the National Institute on Aging Brain 
Physiology and Metabolism Section (Bethesda, MD) by gas chromatography as previously 
described [47]. Plasma fatty acids are expressed as a percentage of total esterified fatty 
acids. Composite fatty acid indices (n-6 in HUFA score and EPA+DHA) were calculated as 
described by Stark [43].
Ramsden et al. Page 4














All analyses were conducted using Stata version 13 (College Station, Texas) and followed 
intention-to-treat principle. To estimate the headache-related clinical measures for the 11 
participants (six in the L6 group, five in the H3-L6 group) who had missing data at week 12, 
we used multiple imputation (MI). The MI regression model consisted of independent 
variables with the other headache-related measures at baseline plus age, gender, and 
intervention group.
We used a Wilcoxon matched-pairs signed-ranks test to assess differences in pre-to-post 
intervention values of the BSI-18 and SF-12 subscales within each diet group. To determine 
whether diet group assignment had an effect on the post-intervention value of each variable, 
we used an analysis of covariance including the baseline value of each respective variable. 
To determine whether diet group assignment had an effect on the likelihood of experiencing 
substantial mental or physical impairments, we used logistic regression models, adjusting for 
the respective baseline value of each outcome.
For the fatty acids, we employed a combination of non-parametric and parametric 
approaches (normalizing variables when necessary) using all available data without 
imputations. The effects of changes in plasma fatty acids on post-intervention clinical 
outcomes were calculated using regression models adjusted for the baseline values of each 
outcome and fatty acid.
3. Results
Sixty-seven subjects with CDH were randomized to either the H3-L6 or L6 intervention. 
Fifty-six participants (28 in each group) completed the 12-week intervention phase, but data 
from all 67 randomized participants were included in the analysis. Figure 2 shows how the 
participants were processed throughout the trial.
3.1. Baseline demographic and clinical characteristics
The H3-L6 and L6 groups had comparable baseline demographic and clinical characteristics 
(Table 1) [34]. Participants reported an average of 23 headache days per month and 10 
headache hours per day, despite taking an average of 6 different headache-related 
medications. Mean scores for the HIT-6 at baseline (60.8, SD 4.9) were consistent with 
severe adverse impact on headache-specific quality of life [3].
3.2 Changes in psychological distress (BSI-18) and health-related quality of life (SF-12)
Table 2 summarizes the effect of the H3-L6 and L6 diets on the BSI-18 and SF-12 scores 
over the 12-week trial. At baseline, there was no statistically significant difference between 
the diet groups. Compared to baseline, participants in the H3-L6 group (but not the L6 
group) experienced statistically significant reductions in psychological distress and 
improvements in HRQOL (p-values < 0.05). Compared to the L6 intervention, participants 
in the H3-L6 intervention group experienced statistically significant reductions in 
psychological distress (mean difference in BSI-18 scores at week 12 was −6.56; 95% 
confidence interval (CI): −11.43, −1.69). Participants in the H3-L6 intervention group also 
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experienced statistically significant improvements in HRQOL, as measured by the SF-12 
mental health summary (mean difference 6.01; 95% CI: 0.57, 11.45) and the SF-12 physical 
health summary (mean difference 6.65; 95% CI; 2.14, 11.16). Participants in the H3-L6 
group experienced statistically significant improvements in most, but not all, subdomains of 
the BSI-18 and SF-12 compared to the L6 group. Changes in BSI-18 and SF-12 subdomains 
can be found in Supplementary Table S4.
3.3 Changes in the number of people experiencing substantial physical or mental 
impairment
Figure 3 shows the change in the number of cases of substantial health impairment as 
defined by cutoff points for BSI-18, SF-12, HIT-6, and headache days per month. Each bar 
chart represents the percentage of the sample with substantial impairment at baseline and 
week 12. At baseline, a majority of the subjects experienced substantial to disabling 
headache-related impairments—70% had greater than or equal to 20 headache days per 
month and 88% had a HIT-6 score of 56 or more. There were no statistically significant 
between-group differences at baseline for any of the outcomes. By week 12, subjects in the 
H3-L6 group had improvements in four of the five indicators shown, with statistically 
significant between-group differences at the 0.01 level for HIT-6 and headache days per 
month and at the 0.05 level for the SF-12 physical health measure and the BSI-18.
3.4 Diet-induced changes in plasma n-3 and n-6 fatty acids
Compared to baseline, both interventions significantly increased plasma n-3 EPA and DHA, 
and reduced the n-6 in HUFA score (Table 3). Compared to the L6 intervention, the H3-L6 
intervention had significantly greater increases in n-3 EPA and DHA and greater reduction 
in n-6 arachidonic acid (AA) and n-6 in HUFA score. Both interventions produced 
comparable, statistically significant reductions in plasma n-6 LA.
3.5 Association between 12-week changes in plasma fatty acids and clinical measures
For each standard deviation increase in plasma DHA, we observed a 16% reduction in the 
number of headache days per month (p<0.001), a 24% reduction in the number of headache 
hours per day (p<0.001), and a 44% reduction in the number of severe headache hours per 
day (p<0.001)(Table 4). Increases in DHA were also related to improvements in the 
functional dimensions of pain (p=0.005), but were unrelated to psychological dimensions of 
pain. Increases in EPA were related to decreased pain frequency and severity (p<0.001) and 
improvements in the functional dimensions of pain (p=0.009), and tended to correlate with 
reduced psychological distress (p=0.022).
Decreases in n-6 LA were strongly related to decreased pain frequency and intensity, but 
unrelated to functional and psychological dimensions of pain. For each standard deviation 
decrease in LA, there was a 15% decrease in headache days per month (p=0.001), a 32% 
decrease in headache hours per day (p<0.001) and a 56% reduction in the number of severe 
headache hours per day (p<0.001). Decreases in n-6 AA were not related to improvements in 
physical or psychological dimensions of pain, but did correlate with improvement in 
physical function. Changes in the n-6 in HUFA and EPA+DHA composite scores were 
related to decreased pain frequency and intensity (p<0.001) and improvements in the 
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functional dimensions of pain (p=0.006), but were unrelated to changes in the psychological 
dimensions of pain.
4. Discussion
This population of subjects with CDH had frequent and often severe physical pain, and 
substantial headache-related impairments in psychological distress and HRQOL. We 
previously demonstrated that the combination of increasing dietary n-3 fatty acids with 
concurrent reduction in n-6 LA (the H3-L6 intervention) produced statistically significant, 
clinically relevant pain reduction, and reduced headache-related disability (HIT-6) [34]. In 
the present analysis, the H3-L6 intervention was found to significantly reduce psychological 
distress, improve physical and mental HRQOL, and significantly reduce the proportion of 
subjects with moderate to severe headache impact and physical impairment. These clinical 
improvements were accompanied by reduced use of headache-related analgesic and 
adjunctive medications, suggesting that the beneficial effects of the H3-L6 intervention were 
not due to changes in psychoactive medication use. These findings demonstrate that the 
beneficial effects of the H3-L6 intervention extended beyond pain reduction, favorably 
impacting the quality-of-life and function of this chronic headache population. However, it is 
not yet clear whether these improvements in psychological distress and HRQOL were 
secondary to reduction in physical pain, or to more direct mechanism(s) targeting anxiety or 
psychological resiliency.
4. 1 Dietary n-3 and n-6 fatty acids and physical pain
Physical pain reduction in the H3-L6 group may be due to diet-induced alteration in the 
balance of pro- and anti-nociceptive lipid-autacoids derived from n-6 and n-3 fatty acids 
(e.g. endovanilloids, endocannabinoids, eicosanoids, resolvins, protectins). Notably, 2-series 
prostaglandins derived from n-6 arachidonic acid can elicit migraines in humans [2], and 
monohydroxy derivatives of n-6 LA have demonstrated pro-nociceptive properties in rodent 
pain models [32; 33]. By contrast, several families of mediators derived from n-3 EPA and 
DHA have demonstrated anti-nociceptive actions in rodent pain models [31; 39; 53; 55]. 
Hence, diet-induced reductions in pro-nociceptive mediators and increases in anti-
nociceptive mediators represent a relatively straightforward, plausible mechanism 
underlying pain relief.
4. 2 Dietary n-3 and n-6 fatty acids and psychological distress
Several, but not all, randomized controlled trials testing n-3 supplement interventions 
reported substantial reductions of depressive symptoms. Meta-analyses of randomized 
controlled trials have reported that EPA predominant n-3 supplements reduce depressive 
symptoms among subjects with clinically significant depressive illnesses [44], [13]. These 
findings are consistent with epidemiological studies [14] and rodent models [42]. Proposed 
mechanisms include diet-induced alterations in monoamine neurotransmitter metabolism 
[17; 45], endocannabinoid signaling [10], immune activation [6; 9], and hypothalamic-
pituitary axis activation [5].
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Patients with physical pain are at increased risk of developing a first episode of depressive 
and anxiety disorders [12]. Given the adverse effect of physical pain on psychological 
health, the finding in the present trial that marked reduction in physical pain in the H3-L6 
group was accompanied by reduced psychological distress is perhaps not surprising. 
However, it is not clear whether the reduction in psychological distress was secondary to 
relief of physical pain, or to a more direct mechanism affecting psychological aspects of the 
pain experience. Since the BSI-18 somatization subscale includes somatic symptoms often 
experienced during migraines (e.g., nausea, tingling), the beneficial effects of the H3-L6 
intervention on migraine frequency may have contributed to reductions in BSI-18.
Chronic pain has well-known adverse impacts on social and family relationships, job status, 
and financial security, which in turn can promote psychological distress [15]. Pain relief may 
not quickly lead to improvements in these social and financial consequences of chronic pain; 
therefore, there may be a substantial lag between reductions in physical pain and consequent 
psychological distress. Notably, the maximal clinical efficacy of some antidepressant 
medications for treating major depression does not occur for several weeks or longer [11; 
49]. Moreover, because participants in the present trial did not have moderate to severe 
levels of depression at baseline it was unlikely that significant reductions in depressive 
symptoms would be detected [20]. Hence, the 12-week intervention period in the present 
trial may not have been of sufficient duration to produce maximal improvements in 
psychological distress. Future, longer trials, including subjects with moderate to severe 
depressive symptoms, are needed to establish whether the H3-L6 intervention can produce 
more marked and sustained psychological improvements.
Reductions in physical pain and psychological distress in the H3-L6 group were 
accompanied by improvements in physical and mental function, and reductions in the 
percentages of subjects meeting cutoff values indicative of moderate-to-severe physical and 
psychological impairment and disability. The robustness of these findings indicates that the 
intervention had a broad beneficial impact on the lives of participants randomized to the H3-
L6 group in this population. If these results are reproducible in other populations with severe 
headaches, and perhaps other chronic pain populations, this dietary approach would 
represent a novel therapeutic option for treating pain, common pain-related comorbidities, 
and functional consequences of chronic pain.
4.3 Mechanistic considerations linking n-3 and n-6 fatty acids to clinical improvements
Physical pain reduction was closely correlated with increases in plasma n-3 EPA and DHA, 
and reduction in n-6 LA, but was not related to changes in plasma n-6 AA. These findings 
are consistent with the hypothesis that changes in anti- and pro-nociceptive lipid mediators 
derived from n-3 EPA and DHA and n-6 LA respectively, could have contributed to the 
observed anti-nociception. Anti-nociceptive mediators derived from DHA include D-series 
resolvins [31; 53], neuroprotectins [30; 52], maresins [39], and DHA-epoxides [39]; anti-
nociceptive mediators derived from EPA include E-series resolvins [31] and EPA-epoxides 
[27]. Pro-nociceptive mediators derived from LA include hydroxyoctadecadienoic acids [32; 
33] and linoleoylethanolamine [28]. The lack of association between changes in plasma n-6 
AA and pain reduction is somewhat surprising since AA is the precursor to prostaglandins 
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that are classically linked to headache pathogenesis. Notably, AA is also the precursor to 
lipid mediators with anti-nociceptive properties (eg, epoxyeicosatrienoic acids, lipoxins), 
which might counteract the pro-nociceptive effects of prostaglandins. Increases in plasma 
n-3 EPA and DHA and reductions in n-6 AA were related to improvement in functional 
dimensions of pain. These collective biochemical findings suggest that both n-3 and n-6 
fatty acids contributed to the beneficial effects of the intervention.
4.4 Limitations
The present trial was relatively small and of short duration. In addition, because targeted 
dietary fatty acids could not be altered as independent variables, we cannot rule out the 
possibility that changes in other nutrients could have contributed to the favorable effects of 
the H3-L6 intervention. Therefore the present trial should be replicated in a larger and 
longer trial, with nutrients altered as controlled variables.
4.4 Future directions
Human trials are needed to better characterize the effects of the H3-L6 intervention on the 
many specific lipid autacoids linked to nociception and psychological distress (e.g. 
prostanoids, endovanilloids, endocannabinoids, maresins), and to investigate the relationship 
of these biochemical changes to physical and psychological dimensions of the pain 
experience. Future trials should also capture daily measures of both physical pain and 
psychological distress in order to investigate the directionality and temporal relationship 
between these different aspects of pain. Animal studies are needed to characterize diet-
induced biochemical alterations in pain signaling pathways and specific peripheral and 
central brain nervous system regions linked to pain processing and psychological distress.
4.5 Summary & Conclusion
Targeted dietary manipulation of n-3 and n-6 fatty acids reduced physical pain and 
psychological distress, and improved HRQOL and physical function in a chronic headache 
population. Future trials are needed to better define the role that targeted dietary alterations 
could play as a complementary strategy for managing the psychological distress and 
physical impairments that often accompany chronic pain.
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Fig. 1. Pain reduction induced by H3-L6 and L6 dietary interventions
The H3-L6 intervention produced statistically significant, clinically relevant reductions in 
pain frequency and intensity in a population with Chronic Daily Headache.
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Fig. 2. CONSORT Trial Profile (Adapted from PAIN publication32)
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Fig. 3. Proportion of subjects experiencing substantial physical or mental impairment
Subjects in the H3-L6 group had statistically significant improvements in HIT-6, headache 
days per month, SF-12 physical health and BSI-18.
*p-value from logistic regression for effect of diet group on 12-week outcomes, adjusted for 
baseline values.
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Table 1





Age, y, mean (SD) 41 (13.4) 42 (11.1)
Female, n (%) 28 (84.8) 30 (88.2)
Education, n (%)
  High school 2 (6.1) 2 (6.2)
  Attended college 18 (54.5) 17 (53.1)
  Master’s degree or higher 13 (40.6) 13 (39.4)
% Chronic migraineb, n (%) 26 (78.8) 24 (70.6)
Headache Impact Test (HIT-6), mean (SD) 61.0 (4.32) 60.6 (5.56)
Headache days per month, mean (SD) 23.3 (20.9, 25.8) 23.2 (20.2, 25.8)
Headache hours per day, mean (SD) 10.2 (8.4, 12.3) 9.8 (8.1, 11.8)
Number of different headache-related
medications reported, mean (SD)
6.4 (3.4) 5.6 (3.3)
  Number using antidepressantsd, n (%) 11 (33.3) 14 (41.2)
    Two or more antidepressants, n (%) 3 (9.1) 2 (5.9)
  Number using anticonvulsantsd, n (%) 12 (36.4) 11 (32.4)
    Two or more anticonvulsants, n (%) 3 (9.1) 2 (5.9)
  Number using anxiolyticsd, n (%) 6 (18.2) 6 (17.6)
    Two or more anxiolytics, n (%) 1 (3.0) 0 (0.0)
a
Adapted from PAIN publication13.
b
Subjects classified as chronic migraine met International Headache Disorders-2 criteria. Subjects classified as Chronic Daily Headache (CDH) 
with migraine features had some characteristics of migraine (e.g. unilateral, pulsating, severe, sensory sensitivity, or aggravated by physical 
activity) but did not meet all criteria needed for chronic migraine diagnosis. Subjects classified with CDH without migraine features had no 
evidence of migraine.
c
95% confidence interval around the median per binomial-based method in Stata 12.
d
Headache medication categories are shown in Supplementary Table S3.
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